|
1
|
Kantoff PW, Higano CS, Shore ND, Berger
ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims
RB, et al: Sipuleucel-T immunotherapy for castration-resistant
prostate cancer. N Engl J Med. 363:411–422. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cheever MA and Higano CS: PROVENGE
(sipuleucel-T) in prostate cancer: The first FDA-approved
therapeutic cancer vaccine. Clin Cancer Res. 17:3520–3526. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Comiskey MC, Dallos MC and Drake CG:
Immunotherapy in prostate cancer: Teaching an old dog new tricks.
Curr Oncol Rep. 20:752018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hrouda D, Todryk SM, Perry MJ,
Souberbielle BE, Kayaga J, Kirby RS and Dalgleish AG: Allogeneic
whole-tumour cell vaccination in the rat model of prostate cancer.
BJU Int. 86:742–748. 2000. View Article : Google Scholar
|
|
5
|
Michael A, Ball G, Quatan N, Wushishi F,
Russell N, Whelan J, Chakraborty P, Leader D, Whelan M and Pandha
H: Delayed disease progression after allogeneic cell vaccination in
hormone-resistant prostate cancer and correlation with immunologic
variables. Clin Cancer Res. 11:4469–4478. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Higano CS, Corman JM, Smith DC, Centeno
AS, Steidle CP, Gittleman M, Simons JW, Sacks N, Aimi J and Small
EJ: Phase 1/2 dose-escalation study of a GM-CSF-secreting,
allogeneic, cellular immunotherapy for metastatic
hormone-refractory prostate cancer. Cancer. 113:975–984. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dalgleish AG, Stebbing J, Adamson DJ, Arif
SS, Bidoli P, Chang D, Cheeseman S, Diaz-Beveridge R,
Fernandez-Martos C, Glynne-Jones R, et al: Randomised, open-label,
phase II study of gemcitabine with and without IMM-101 for advanced
pancreatic cancer. Br J Cancer. 115:789–796. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Petrou S, Mamais I, Lavranos G, P
Tzanetakou I and Chrysostomou S: Effect of vitamin D
supplementation in prostate cancer: A systematic review of
randomized control trials. Int J Vitam Nutr Res. 88:100–112. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shang Z, Wang X, Yan H, Cui B, Wang Q, Wu
J, Cui X, Li J, Ou T and Yang K: Intake of non-steroidal
anti-inflammatory drugs and the risk of prostate cancer: A
meta-analysis. Front Oncol. 8:4372018. View Article : Google Scholar
|
|
10
|
Michael A, Hedayati B and Dalgleish AG:
Disease regression in malignant melanoma: Spontaneous resolution or
a result of treatment with antioxidants, green tea, and pineapple
cores? A case report. Integr Cancer Ther. 6:77–99. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu WM and Dalgleish AG: Naltrexone at low
doses (LDN) and its relevance to cancer therapy. Expert Rev
Anticancer Ther. Feb 7–2022.(Epub ahead of print). View Article : Google Scholar
|
|
12
|
Cant R, Dalgleish AG and Allen RL:
Naltrexone inhibits IL-6 and TNFα production in human immune cell
subsets following stimulation with ligands for intracellular
toll-like receptors. Front Immunol. 8:8092017. View Article : Google Scholar
|
|
13
|
Liu WM, Scott KA, Dennis JL, Kaminska E,
Levett AJ and Dalgleish AG: Naltrexone at low doses upregulates a
unique gene expression not seen with normal doses: Implications for
its use in cancer therapy. Int J Oncol. 49:793–802. 2016.
View Article : Google Scholar
|
|
14
|
Fowler DW, Copier J, Wilson N, Dalgleish
AG and Bodman-Smith MD: Mycobacteria activate γδ T-cell anti-tumour
responses via cytokines from type 1 myeloid dendritic cells: A
mechanism of action for cancer immunotherapy. Cancer Immunol
Immunother. 61:535–547. 2012. View Article : Google Scholar : PubMed/NCBI
|
